We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA: Assessment of Ranbaxy’s India Site Shows No Risk to Public Health

EMA: Assessment of Ranbaxy’s India Site Shows No Risk to Public Health

June 6, 2014

European regulators said they will reinstate a good manufacturing practice certification for Ranbaxy’s manufacturing facility in Toansa, India, following an inspection that found the generic drugmaker had addressed reported GMP violations. 

The European Medicines Agency said an assessment of the plant that produces active pharmaceutical ingredients (API) found “a number of GMP deficiencies,” but that the deficiencies do not pose a risk to public health.

The agency had suspended Ranbaxy’s GMP certificate in January following an FDA inspection that found significant GMP violations, such as retesting of raw materials, intermediate drug products and APIs that failed analytical testing to produce passing results.

A team of investigators from Germany, Ireland, the UK, Switzerland and Australia subsequently inspected the site. The investigators concluded that the manufacturer had put in place “corrective and preventative measures” and that there was no evidence that drugs made with APIs from Toansa were of unacceptable quality in the EU market, according to the EMA.

“This conclusion was supported by tests of samples of these medicines, all of which met the correct quality specifications,” the EMA said.

In January, the FDA prohibited the plant from manufacturing and distributing APIs for U.S. products. In March, Indian authorities suspended the Toansa facility’s certification to export APIs to Europe. Ranbaxy voluntarily stopped exports to Europe from the plant in January.

The EMA said it would continue to closely supervise the Toansa site, in collaboration with India and other regulatory authorities around the world.

The company declined to comment on the EMA’s announcement.

Ensure that your company prevents GMP violations in the first place; get GMP Training for Drugmakers today!

Pharmaceuticals GMPs

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing